Skip to main content
SpringerLink
Log in

Effects of rimonabant on progression of atherosclerosis: Increased risks and doubtful benefits

  • Clinical Trials Report
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ogden CL, Carroll MD, Curtin LR, et al.: Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006, 295:1549–1555.

    Article  PubMed  CAS  Google Scholar 

  2. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718.

    Article  PubMed  CAS  Google Scholar 

  3. Castro JP, El-Atat FA, McFarlane SI, et al.: Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep 2003, 5:393–401.

    Article  PubMed  Google Scholar 

  4. Despres JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature 2006, 444:881–887.

    Article  PubMed  CAS  Google Scholar 

  5. Karam JG, El-Sayegh S, Nessim F, et al.: Medical management of obesity: an update. Minerva Endocrinol 2007, 32:185–207.

    PubMed  CAS  Google Scholar 

  6. Despres JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121–2134.

    Article  PubMed  CAS  Google Scholar 

  7. Van Gaal LF, Rissanen AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389–1397.

    Article  PubMed  Google Scholar 

  8. Sanofi-Aventis: Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO). Available at http://www.clinicaltrials.gov/ct2/show/NCT00263042?term=crescendo&rank=1. Accessed January 28, 2008.

Download references

Authors
  1. Girardin Jean-Louis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ferdinand Zizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samy I. McFarlane
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jean-Louis, G., Zizi, F. & McFarlane, S.I. Effects of rimonabant on progression of atherosclerosis: Increased risks and doubtful benefits. Curr Cardio Risk Rep 3, 79–80 (2009). https://doi.org/10.1007/s12170-009-0013-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-009-0013-z

Keywords

Search

Navigation